Atara Biotherapeutics, Inc. - Common Stock (ATRA)

Historical Holders from Q4 2014 to Q3 2025

Symbol
ATRA on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
8.56M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
15
Holdings value
$215
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
1
Number of buys
1
Average Value change %
+0%
Average buys %
+0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Panacea Innovation Ltd 20% +0.05% 1.71M +4.54% Panacea Innovation Limited 15 Aug 2025
Adiumentum Capital Fund I LP 19.99% 1.37M Adiumentum Capital Fund I LP 14 May 2025

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 15 $215 +$215 $14.33 1
2025 Q1 0 $0 -$839 0
2024 Q4 63 $839 $13.32 2
2024 Q3 35 $285 -$1.51M $8.14 1
2024 Q2 182K $1.51M -$88.6M $8.50 5
2024 Q1 83.2M $57.8M +$13.5M $0.69 80
2023 Q4 64.7M $33.2M -$41.7M $0.51 89
2023 Q3 88.2M $131M -$3.29M $1.48 108
2023 Q2 90.4M $145M -$23.3M $1.61 115
2023 Q1 103M $298M +$14.4M $2.90 124
2022 Q4 97.4M $319M -$2.17M $3.28 138
2022 Q3 97.7M $369M -$18.9M $3.78 149
2022 Q2 99.8M $777M +$14M $7.79 132
2022 Q1 97.9M $909M +$12.5M $9.29 139
2021 Q4 93.3M $1.47B +$63.7M $15.76 137
2021 Q3 87.8M $1.57B +$69.6M $17.90 138
2021 Q2 85.9M $1.34B -$10.1M $15.55 144
2021 Q1 85.7M $1.23B -$3.13M $14.36 148
2020 Q4 86.6M $1.7B +$61.2M $19.63 144
2020 Q3 83.8M $1.09B +$59.5M $12.96 138
2020 Q2 77.6M $1.13B +$245M $14.57 121
2020 Q1 62.6M $532M +$2.83M $8.51 106
2019 Q4 61.1M $1.01B +$38.3M $16.47 112
2019 Q3 59M $833M +$118M $14.12 111
2019 Q2 50.3M $1.01B +$11.3M $20.11 114
2019 Q1 48.8M $1.94B +$25.2M $39.75 118
2018 Q4 48.3M $1.68B +$62.5M $34.74 119
2018 Q3 46.3M $1.92B -$3.17M $41.35 114
2018 Q2 46.5M $1.71B +$103M $36.75 122
2018 Q1 43.6M $1.7B +$562M $39.00 113
2017 Q4 29.8M $542M +$35.7M $18.10 82
2017 Q3 26.6M $441M +$15.3M $16.55 80
2017 Q2 25.7M $360M +$19.8M $14.00 80
2017 Q1 24M $493M +$57M $20.55 82
2016 Q4 23.2M $330M +$8.11M $14.20 83
2016 Q3 22.4M $479M +$15.3M $21.39 72
2016 Q2 21.6M $486M +$46.7M $22.51 70
2016 Q1 19.8M $377M +$7.12M $19.03 69
2015 Q4 19.3M $509M -$22M $26.41 83
2015 Q3 19.5M $613M +$197M $31.44 87
2015 Q2 13.2M $696M +$108M $52.76 74
2015 Q1 11.2M $462M +$186M $41.57 52
2014 Q4 6.73M $172M +$162M $26.75 39